Methotrexate reduces the complications of endophthalmitis resulting from intravitreal injection compared with dexamethasone in a rabbit model

Investigative Ophthalmology and Visual Science

Volumn 47, Issue 4, 2006, Pages 1516-1521

  Deng, Sophie X ^a   Penland, Susan ^b   Gupta, Sumit ^a   Fiscella, Richard ^b   Edward, Deepak P ^a   Tessler, Howard H ^a   Goldstein, Debra A ^a,b  

^a UNIVERSITY OF ILLINOIS   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; METHOTREXATE; FOLIC ACID ANTAGONIST; GLUCOCORTICOID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIMICROBIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; ENDOPHTHALMITIS; HISTOPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; STAPHYLOCOCCUS EPIDERMIDIS; TREATMENT OUTCOME; ANIMAL; BACTERIAL COUNT; BACTERIAL EYE INFECTION; COMPARATIVE STUDY; DISEASE MODEL; DRUG EFFECT; INJECTION; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; RABBIT; STAPHYLOCOCCUS INFECTION; VITREOUS BODY;

ANIMALS; COLONY COUNT, MICROBIAL; DEXAMETHASONE; DISEASE MODELS, ANIMAL; ENDOPHTHALMITIS; EYE INFECTIONS, BACTERIAL; FOLIC ACID ANTAGONISTS; GLUCOCORTICOIDS; INJECTIONS; METHOTREXATE; MICROBIAL SENSITIVITY TESTS; RABBITS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS EPIDERMIDIS; VITREOUS BODY;

EID: 33646012021     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.05-0880     Document Type: Article

References (33)

1. Fleming GF, Schilsky RL. Antifolates: the next generation. Semin Oncol. 1992;19:707-719.
2. Djalilian AR, Nussenblatt RB. Immunosuppression in uveitis. Ophthalmol Clin North Am. 2002;15:395-404.
3. Deschenes J. Therapeutics for future treatment of uveitis (in French). Bull Soc Belge Ophtalmol. 2000;276:7-11.
4. Van Gelder RN, Kaplan HJ. Immunosuppression in uveitis therapy. Springer Semin Immunopathol. 1999;21:179-190.
5. Kaklamani VG, Kaklamanis PG. Treatment of Behçet's disease: an update (published correction in appears in Semin Arthritis Rheum 2001;31:69). Semin Arthritis Rheumatism. 2001;30:299-312.
6. Samson CM, Waheed N, Baltatzis S, Foster CS. Methotrexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patients. Ophthalmology. 2001;108:1134-1139.
7. Velez G, Boldt HC, Whitcup SM, Nussenblatt RB, Robinson MR. Local methotrexate and dexamethasone phosphate for the treatment of recurrent primary intraocular lymphoma. Ophthalmic Surg Lasers. 2002;33:329-333.
8. Fishburne BC, Wilson DJ, Rosenbaum JT, Neuwelt EA. Intravitreal methotrexate as an adjunctive treatment of intraocular lymphoma. Arch Ophthalmol. 1997;115:1152-1156.
9. Smith JR, Rosenbaum JT, Wilson DJ, et al. Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement. Ophthalmology. 2002;109:1709-1716.
10. Velez G, Yuan P, Sung C, et al. Pharmacokinetics and toxicity of intravitreal chemotherapy for primary intraocular lymphoma. Arch Ophthalmol. 2001;119:1518-1524.
11. Martidis A, Duker JS, Greenberg PB, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology. 2002;109:920-927.
12. Park CH, Jaffe GJ, Fekrat S. Intravitreal triamcinolone acetonide in eyes with cystoid macular edema associated with central retinal vein occlusion. Am J Ophthalmol. 2003;136:419-425.
13. Jonas JB, Kreissig I, Degenring RF. Intravitreal triamcinolone acetonide for pseudophakic cystoid macular edema. Am J Ophthalmol. 2003;136:384-386.
14. Jonas JB, Kreissig I, Degenring RF. Intravitreal triamcinolone acetonide as treatment of macular edema in central retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2002;240:782-783.
15. Antcliff RJ, Spalton DJ, Stanford MR, Graham EM, ffytche TJ, Marshall J. Intravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study. Ophthalmology. 2001;108:765-772.
16. Young S, Larkin G, Branley M, Lightman S. Safety and efficacy of intravitreal triamcinolone for cystoid macular oedema in uveitis (comment). Clin Exp Ophthalmol. 2001;29:2-6.
17. Jonas JB, Kreissig I, Degenring R. Intraocular pressure after intravitreal injection of triamcinolone acetonide. Br J Ophthalmol. 2003;87:24-27.
18. Sutter FK, Gillies MC. Pseudo-endophthalmitis after intravitreal injection of triamcinolone. Br J Ophthalmol. 2003;87:972-974.
19. Roth DB, Chieh J, Spirn MJ, Green SN, Yarian DL, Chaudhry NA. Noninfectious endophthalmitis associated with intravitreal triamcinolone injection. Arch Ophthalmol. 2003;121:1279-1282.
20. Moshfeghi DM, Kaiser PK, Scott IU, et al. Acute endophthalmitis following intravitreal triamcinolone acetonide injection. Am J Ophthalmol. 2003;136:791-796.
21. West ES, Behrens A, McDonnell PJ, Tielsch JM, Schein OD. The incidence of endophthalmitis after cataract surgery among the U.S. Medicare population increased between 1994 and 2001. Ophthalmology. 2005;112:1388-1394.
22. Han DP, Wisniewski SR, Wilson LA, et al. Spectrum and susceptibilities of microbiologic isolates in the Endophthalmitis Vitrectomy Study (published correction appears in Am J Ophthalmol 1996;122:920). Am J Ophthalmol. 1996;122:1-17.
23. Bodet CA 3rd, Jorgensen JH, Drutz DJ. Antibacterial activities of antineoplastic agents. Antimicrob Agents Chemother. 1985;28:437-439.
24. Kruszewska H, Zareba T, Tyski S. Antimicrobial activity of selected non-antibiotics: activity of methotrexate against Staphylococcus aureus strains. Acta Poloniae Pharma. 2000;57:117-119.
25. Bartlett MS, Shaw M, Navaran P, Smith JW, Queener SF. Evaluation of potent inhibitors of dihydrofolate reductase in a culture model for growth of Pneumocystis carinii. Antimicrob Agents Chemother. 1995;39:2436-2441.
26. National Committee for Clinical Laboratory Standards 2000. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard, M7-A5. 5th ed. National Committee for Clinical Laboratory Standards Wayne, PA.
27. Pleyer U, Mondino BJ, Adamu SA, Pitchekian-Halabi H, Engstrom RE, Glasgow BJ. Immune response to Staphylococcus epidermidis-induced endophthalmitis in a rabbit model. Invest Ophthalmol Vis Sci. 1992;33:2650-2663.
28. Cronstein BN, Naime D, Ostad E. The antiinflammatory mechanism of methotrexate: increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest. 1993;92:2675-2682.
29. Cronstein BN. Adenosine, an endogenous anti-inflammatory agent. J Appl Physiol. 1994;76:5-13.
30. Cronstein BN. The mechanism of action of methotrexate. Rheum Dis Clin North Am. 1997;23:739-755.
31. Shah GK, Stein JD, Sharma S, et al. Visual outcomes following the use of intravitreal steroids in the treatment of postoperative endophthalmitis (comment). Ophthalmology. 2000;107:486-489.
32. Belgi G, Friedmann PS. Traditional therapies: glucocorticoids, azathioprine, methotrexate, hydroxyurea. Clin Exp Dermatol. 2002;27:546-554.
33. Westfall AC, Osborn A, Kuhl D, Benz MS, Mieler WF, Holz ER. Acute endophthalmitis incidence intravitreal triamcinolone. Arch Ophthalmol. 2005;123:1075-1077.